In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Clinical significance of serum soluble interleukin-2 receptor in patients with primary central nervous system lymphoma

    Final Number:
    712

    Authors:
    Masaki Okada MD PhD; Daisuke Ogawa MD, PhD; Tetsuhiro Hatakeyama; Aya Shinomiya; Keisuke Miyake MD PhD; Nobuyuki Kawai MD; Takashi Tamiya MD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: Soluble interleukin-2 receptor (sIL-2R) is well known as a disease marker of systemic malignant lymphomas. However, clinical significance of sIL-2R in primary central nervous system lymphoma (PCNSL) is still unclear. We investigated relationships between serum sIL-2R or other clinical values and the prognosis in patients with PCNSL.

    Methods: The patients were 21 men and 22 women, mean age 66.5y, treated in our hospital from November 2002 to March 2014. Mean follow-up period was 17.4 months ranging from one to 122 months. For the statistical analysis, the patients were grouped by the age (cut off: 70y), Karnofsky performance status (KPS. cut off; 70), the serum level of sIL-2R (cut off: 550IU/mL), LDH (cut off: 220U/mL) and standardized uptake value (SUVmax. cut off: 12) measured by 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) as tumor aggressiveness before the treatment.

    Results: The serum level of sIL-2R was not affected by the age, but elevated in lower KPS group (p=0.0457). Serum level of sIL-2R and LDH related neither FDG uptake nor survival. Kaplan-Meier analysis exhibited higher uptake on FDG-PET associated with poor survival (p=0.0186), and mild tendencies of poor survival among the aged-population (p=0.1854) and lower KPS group (p=0.2822). Our results indicated sIL-2R had no prognostic impact but some relationship to the patient condition.

    Conclusions: Our study illustrates the serum level of sIL-2R reflects poorer systemic and/or neurological condition that might lead to worse prognosis. SUVmax in FDG-PET related to the patient survival.

    Patient Care: It would be useful for the evaluation of systemic/neurological condition of PCNSL patients. The measurement of sIL-2R level would be an aid to forecast systemic relapse of lymphoma.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Explain knowledge about sIL-2R and clinical applications of its measurement. 2) Judge how systemic and/or neurological condition in patients with PCNSL impacts on their prognoses. 3) Compare and contrast the usefulness and implication of sIL-2R and FDG-PET for predicting the prognosis of PCNSL.

    References: Kawai N, Zhen HN, Miyake K, Yamamaoto Y, Nishiyama Y, Tamiya T. Prognostic value of pretreatment 18F-FDG PET in patients with primary central nervous system lymphoma: SUV-based assessment. J Neurooncol. 2010 Nov; 100(2):225-32.

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy